233 related articles for article (PubMed ID: 27136302)
41. Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan.
Ward WH; Holdgate GA; Rowsell S; McLean EG; Pauptit RA; Clayton E; Nichols WW; Colls JG; Minshull CA; Jude DA; Mistry A; Timms D; Camble R; Hales NJ; Britton CJ; Taylor IW
Biochemistry; 1999 Sep; 38(38):12514-25. PubMed ID: 10493822
[TBL] [Abstract][Full Text] [Related]
42. Inhibitor binding studies on enoyl reductase reveal conformational changes related to substrate recognition.
Roujeinikova A; Sedelnikova S; de Boer GJ; Stuitje AR; Slabas AR; Rafferty JB; Rice DW
J Biol Chem; 1999 Oct; 274(43):30811-7. PubMed ID: 10521472
[TBL] [Abstract][Full Text] [Related]
43. Enoyl acyl carrier protein reductase inhibitors: an updated patent review (2011 - 2015).
Zitko J; Doležal M
Expert Opin Ther Pat; 2016 Sep; 26(9):1079-94. PubMed ID: 27399249
[TBL] [Abstract][Full Text] [Related]
44. Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei.
Liu N; Cummings JE; England K; Slayden RA; Tonge PJ
J Antimicrob Chemother; 2011 Mar; 66(3):564-73. PubMed ID: 21393229
[TBL] [Abstract][Full Text] [Related]
45. Combined effect of epigallocatechin gallate and triclosan on enoyl-ACP reductase of Mycobacterium tuberculosis.
Sharma SK; Kumar G; Kapoor M; Surolia A
Biochem Biophys Res Commun; 2008 Mar; 368(1):12-7. PubMed ID: 17996734
[TBL] [Abstract][Full Text] [Related]
46. FabV, the Unique Enoyl-Acyl Carrier Protein Reductase in
Li F; Deng J; Zhang Z; Wang C; Mao Y
Phytopathology; 2024 Apr; 114(4):780-791. PubMed ID: 37913555
[TBL] [Abstract][Full Text] [Related]
47. Characterization of a novel enoyl-acyl carrier protein reductase of diazaborine-resistant Rhodobacter sphaeroides mutant.
Lee IH; Kim EJ; Cho YH; Lee JK
Biochem Biophys Res Commun; 2002 Dec; 299(4):621-7. PubMed ID: 12459184
[TBL] [Abstract][Full Text] [Related]
48. Rational optimization of drug-target residence time: insights from inhibitor binding to the Staphylococcus aureus FabI enzyme-product complex.
Chang A; Schiebel J; Yu W; Bommineni GR; Pan P; Baxter MV; Khanna A; Sotriffer CA; Kisker C; Tonge PJ
Biochemistry; 2013 Jun; 52(24):4217-28. PubMed ID: 23697754
[TBL] [Abstract][Full Text] [Related]
49. Structural and enzymatic analyses reveal the binding mode of a novel series of Francisella tularensis enoyl reductase (FabI) inhibitors.
Mehboob S; Hevener KE; Truong K; Boci T; Santarsiero BD; Johnson ME
J Med Chem; 2012 Jun; 55(12):5933-41. PubMed ID: 22642319
[TBL] [Abstract][Full Text] [Related]
50. Rational design of InhA inhibitors in the class of diphenyl ether derivatives as potential anti-tubercular agents using molecular dynamics simulations.
Kamsri P; Koohatammakun N; Srisupan A; Meewong P; Punkvang A; Saparpakorn P; Hannongbua S; Wolschann P; Prueksaaroon S; Leartsakulpanich U; Pungpo P
SAR QSAR Environ Res; 2014; 25(6):473-88. PubMed ID: 24785640
[TBL] [Abstract][Full Text] [Related]
51. Crystal structures of Enoyl-ACP reductases I (FabI) and III (FabL) from B. subtilis.
Kim KH; Ha BH; Kim SJ; Hong SK; Hwang KY; Kim EE
J Mol Biol; 2011 Feb; 406(3):403-15. PubMed ID: 21185310
[TBL] [Abstract][Full Text] [Related]
52. The X-ray structure of Escherichia coli enoyl reductase with bound NAD+ at 2.1 A resolution.
Baldock C; Rafferty JB; Stuitje AR; Slabas AR; Rice DW
J Mol Biol; 1998 Dec; 284(5):1529-46. PubMed ID: 9878369
[TBL] [Abstract][Full Text] [Related]
53. Mycobacterium tuberculosis enoyl-acyl carrier protein reductase inhibitors as potential antituberculotics: development in the past decade.
Holas O; Ondrejcek P; Dolezal M
J Enzyme Inhib Med Chem; 2015; 30(4):629-48. PubMed ID: 25383419
[TBL] [Abstract][Full Text] [Related]
54. Biochemical and structural basis for Moraxella catarrhalis enoyl-acyl carrier protein reductase (FabI) inhibition by triclosan and estradiol.
Katiki M; Neetu N; Pratap S; Kumar P
Biochimie; 2022 Jul; 198():8-22. PubMed ID: 35276316
[TBL] [Abstract][Full Text] [Related]
55. Biochemical and structural characterization of the trans-enoyl-CoA reductase from Treponema denticola.
Bond-Watts BB; Weeks AM; Chang MC
Biochemistry; 2012 Aug; 51(34):6827-37. PubMed ID: 22906002
[TBL] [Abstract][Full Text] [Related]
56. Role of inhibitor aliphatic chain in the thermodynamics of inhibitor binding to Escherichia coli enoyl-ACP reductase and the Phe203Leu mutant: a proposed mechanism for drug resistance.
Protasevich II; Brouillette CG; Snow ME; Dunham S; Rubin JR; Gogliotti R; Siegel K
Biochemistry; 2004 Oct; 43(42):13380-9. PubMed ID: 15491144
[TBL] [Abstract][Full Text] [Related]
57. Common themes in redox chemistry emerge from the X-ray structure of oilseed rape (Brassica napus) enoyl acyl carrier protein reductase.
Rafferty JB; Simon JW; Baldock C; Artymiuk PJ; Baker PJ; Stuitje AR; Slabas AR; Rice DW
Structure; 1995 Sep; 3(9):927-38. PubMed ID: 8535786
[TBL] [Abstract][Full Text] [Related]
58. A triclosan-resistance protein from the soil metagenome is a novel enoyl-acyl carrier protein reductase: Structure-guided functional analysis.
Kim SH; Khan R; Choi K; Lee SW; Rhee S
FEBS J; 2020 Nov; 287(21):4710-4728. PubMed ID: 32112503
[TBL] [Abstract][Full Text] [Related]
59. Structure-activity studies of the inhibition of FabI, the enoyl reductase from Escherichia coli, by triclosan: kinetic analysis of mutant FabIs.
Sivaraman S; Zwahlen J; Bell AF; Hedstrom L; Tonge PJ
Biochemistry; 2003 Apr; 42(15):4406-13. PubMed ID: 12693936
[TBL] [Abstract][Full Text] [Related]
60. Crystallographic insights into the structure-activity relationships of diazaborine enoyl-ACP reductase inhibitors.
Jordan CA; Sandoval BA; Serobyan MV; Gilling DH; Groziak MP; Xu HH; Vey JL
Acta Crystallogr F Struct Biol Commun; 2015 Dec; 71(Pt 12):1521-30. PubMed ID: 26625295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
